Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis

原文： 2016 年发布于 Medicine (Baltimore)  浏览量：134次

作者： Wu Y. P. Lin T. T. Chen S. H. Xu N. Wei Y. Huang J. B. Sun X. L. Zheng Q. S. Xue X. Y. Li X. D.

作者单位： Department of Urology, Medical University of Vienna, Vienna, Austria. Department of Urology, Jikei University School of Medicine, Tokyo, Japan. Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. Vita-Salute San Raffaele University, Milan, Italy. Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. Department of Urology, Weill Cornell Medical College, New York, New York, USA. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

归属分类：膀胱肿瘤治疗及预后证据

DOI： 10.1016/j.euo.2019.09.008

BACKGROUND: Urological cancers occur worldwide. Many factors, among which the catechol-O-methyltransferase (COMT) Val158Met polymorphism, are said to be associated with the cancer risk. We conducted a meta-analysis to investigate the association between urological cancer susceptibility and COMT Val158Met in different genetic models. METHODS: This study was based on material obtained from the PubMed, HuGENet and Embase databases. Four models including dominant (AA + AG vs. GG), recessive (AA vs. AG + GG), codominant (AA vs. AG, AA vs. GG) and per-allele analysis (A vs. G) were applied. Odds ratios (OR) and the corresponding 95% confidence intervals (CI) were used to evaluate the power of the associations. RESULTS: Fourteen eligible studies comprising 3,285 cases and 3,594 controls were included. Although we could not detect a positive function of the COMT Val158Met polymorphism in urological cancers, the polymorphism might be significantly associated with bladder cancer risk (dominant model [AA + AG vs. GG]: OR = 0.736, 95% CI = 0.586-0.925, I2 = 0.00%; recessive model [AA vs. AG + GG]: OR = 0.822, 95%CI = 0.653-1.035, I2 = 6.30%; codominant model [AA vs. AG]: OR = 0.908, 95% CI = 0.710-1.161, I2 = 0.00%; codominant model [AA vs. GG]: OR = 0.693, 95% CI = 0.524-0.917, I2 = 30.20%; allele analysis [A vs. G]: OR = 0.826, 95%CI = 0.717-0.951, I2 = 30.20%). The same significant associations were not found for kidney cancer and prostate cancer risk in different ethnicities. There also seemed to be no distinct effect of the polymorphism on benign prostatic hyperplasia. CONCLUSIONS: We suggest that bladder cancer but not prostate cancer and kidney cancer could be significantly associated with the Val158Met polymorphism. Interaction of COMT genetic and related environmental factors for urological cancers should not be ignored in future.